NEWS
IBEX ANNOUNCES GALEN 3.0 CANCER DIAGNOSTICS PLATFORM
Ibex Medical Analytics , a leader in AI-powered cancer diagnostics , has announced the launch and rollout of Galen 3.0 – a transformative solution offering new detection capabilities and a broad set of features to support pathologists in the diagnosis of multiple tissue types across various digital pathology workflows .
Galen 3.0 is CE-Marked , approved in additional countries and now generally available to Ibex customers .
Creating a new modality for cancer diagnosis , Galen is one of the first and most widely deployed AI technology in pathology and used in routine clinical practice at laboratories , hospitals and health systems worldwide .
Galen 3.0 incorporates the very latest evolution of Ibex ' s AI algorithms for detecting cancer and other clinically relevant features in prostate , breast and gastric biopsies .
To ensure very high accuracy and generalizability , Ibex trained the Deep Learning networks on huge , enriched data sets from laboratories worldwide that were digitised by multiple scanning systems , including rare prostatic malignancies such as intraductal carcinoma , neuroendocrine tumour , colorectal adenocarcinoma , lymphoma and urothelial carcinoma .
Galen also calculates a Gleason score , tumour size and percentage for each cancer slide , potentially enabling pathologists to save review time and reduce subjectivity .
Galen supports pathologists across numerous diagnostic tasks during the review of breast , prostate and gastric biopsies and helps improve the quality of cancer diagnosis , reduce turnaround time , boost productivity and improve user experience for pathologists . Galen demonstrated outstanding outcomes across clinical studies performed in multiple pathology labs and diagnostic workflows 1 , 2 , 3 , 4 , 5 .
LABEL EXPANSION STRENGTHENS ROCHE ' S PORTFOLIO OF COMPANION DIAGNOSTICS
Roche has announced CE label expansion of the VENTANA PD- L1 ( SP263 ) Assay in non-small cell lung cancer ( NSCLC ) as a companion diagnostic for Tecentriq ( atezolizumab ).
This advances the company ' s commitment to guiding clinical decisionmaking through innovative , high-quality assays that improve patient access to personalised healthcare . The current standard of care for patients with early-stage lung cancer is the removal of the tumour , which may be followed by chemotherapy . Unfortunately , about half of these patients will have their cancer return following surgery . The European Commission approved Tecentriq in June 2022 as adjuvant treatment following surgery and platinum-based chemotherapy for adults whose Stage II-IIIA NSCLC tumours have high PD-L1 protein expression .
The VENTANA PD-L1 ( SP263 ) Assay identifies NSCLC patients who may be eligible for Tecentriq monotherapy in this indication , potentially reducing their risk of disease recurrence or death by more than half .
" With early detection of lung cancer , it is possible to give patients more treatment options and potentially improve a patient ' s outcome ," said Jill German , Head of Pathology Lab at Roche Diagnostics .
" We are proud to offer a PD-L1 test that may qualify lung cancer patients for Tecentriq therapy . With this latest expansion , clinicians can consider multiple targeted immunotherapy options with one test to quickly determine the right treatment for each patient ." �
12 www . intelligenthealth . tech